Halima Amhaoul1, Julie Hamaide2, Daniele Bertoglio1, Stephanie Nadine Reichel1, Jeroen Verhaeghe3, Elly Geerts4, Debby Van Dam4, Peter Paul De Deyn5, Samir Kumar-Singh6, Andrew Katsifis7, Annemie Van Der Linden8, Steven Staelens3, Stefanie Dedeurwaerdere9. 1. Department of Translational Neurosciences, University of Antwerp, Belgium. 2. Department of Translational Neurosciences, University of Antwerp, Belgium; Bio-Imaging Lab, University of Antwerp, Belgium. 3. Molecular Imaging Center Antwerp, University of Antwerp, Belgium. 4. Laboratory of Neurochemistry and Behaviour, University of Antwerp, Belgium. 5. Laboratory of Neurochemistry and Behaviour, University of Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Belgium; Department of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen (UMCG), The Netherlands. 6. Laboratory of Cell Biology & Histology, University of Antwerp, Belgium. 7. Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Australia. 8. Bio-Imaging Lab, University of Antwerp, Belgium. 9. Department of Translational Neurosciences, University of Antwerp, Belgium. Electronic address: stefanie.dedeurwaerdere@uantwerpen.be.
Abstract
AIMS: A hallmark in the neuropathology of temporal lobe epilepsy is brain inflammation which has been suggested as both a biomarker and a new mechanistic target for treatments. The translocator protein (TSPO), due to its high upregulation under neuroinflammatory conditions and the availability of selective PET tracers, is a candidate target. An important step to exploit this target is a thorough characterisation of the spatiotemporal profile of TSPO during epileptogenesis. METHODS: TSPO expression, microglial activation, astrocyte reactivity and cell loss in several brain regions were evaluated at five time points during epileptogenesis, including the chronic epilepsy phase in the kainic acid-induced status epilepticus (KASE) model (n = 52) and control Wistar Han rats (n = 33). Seizure burden was also determined in the chronic phase. Furthermore, ¹⁸F-PBR111 PET/MRI scans were acquired longitudinally in an additional four KASE animals. RESULTS: TSPO expression measured with in vitro and in vivo techniques was significantly increased at each time point and peaked two weeks post-SE in the limbic system. A prominent association between TSPO expression and activated microglia (p < 0.001; r = 0.7), as well as cell loss (p < 0.001; r = -0.8) could be demonstrated. There was a significant positive correlation between spontaneous seizures and TSPO upregulation in several brain regions with increased TSPO expression. CONCLUSIONS: TSPO expression was dynamically upregulated during epileptogenesis, persisted in the chronic phase and correlated with microglia activation rather than reactive astrocytes. TSPO expression was correlating with spontaneous seizures and its high expression during the latent phase might possibly suggest being an important switching point in disease ontogenesis which could be further investigated by PET imaging.
AIMS: A hallmark in the neuropathology of temporal lobe epilepsy is brain inflammation which has been suggested as both a biomarker and a new mechanistic target for treatments. The translocator protein (TSPO), due to its high upregulation under neuroinflammatory conditions and the availability of selective PET tracers, is a candidate target. An important step to exploit this target is a thorough characterisation of the spatiotemporal profile of TSPO during epileptogenesis. METHODS:TSPO expression, microglial activation, astrocyte reactivity and cell loss in several brain regions were evaluated at five time points during epileptogenesis, including the chronic epilepsy phase in the kainic acid-induced status epilepticus (KASE) model (n = 52) and control Wistar Han rats (n = 33). Seizure burden was also determined in the chronic phase. Furthermore, ¹⁸F-PBR111 PET/MRI scans were acquired longitudinally in an additional four KASE animals. RESULTS:TSPO expression measured with in vitro and in vivo techniques was significantly increased at each time point and peaked two weeks post-SE in the limbic system. A prominent association between TSPO expression and activated microglia (p < 0.001; r = 0.7), as well as cell loss (p < 0.001; r = -0.8) could be demonstrated. There was a significant positive correlation between spontaneous seizures and TSPO upregulation in several brain regions with increased TSPO expression. CONCLUSIONS:TSPO expression was dynamically upregulated during epileptogenesis, persisted in the chronic phase and correlated with microglia activation rather than reactive astrocytes. TSPO expression was correlating with spontaneous seizures and its high expression during the latent phase might possibly suggest being an important switching point in disease ontogenesis which could be further investigated by PET imaging.
Entities:
Keywords:
(18)F-PBR111 PET; Brain- and neuroinflammation; Epilepsy; Microglia; Seizure; Translocator protein or peripheral benzodiazepine receptor
Authors: Leah P Dickstein; Jeih-San Liow; Alison Austermuehle; Sami Zoghbi; Sara K Inati; Kareem Zaghloul; Paolo Zanotti-Fregonara; William H Theodore Journal: Epilepsia Date: 2019-05-30 Impact factor: 5.864
Authors: Rachael Garner; Marianna La Rocca; Paul Vespa; Nigel Jones; Martin M Monti; Arthur W Toga; Dominique Duncan Journal: Epilepsia Date: 2019-10-08 Impact factor: 5.864
Authors: Sophie V Vo; Samuel D Banister; Isaac Freelander; Eryn L Werry; Tristan A Reekie; Lars M Ittner; Michael Kassiou Journal: RSC Med Chem Date: 2020-03-12
Authors: Lora D Weidner; Pavitra Kannan; Nicholas Mitsios; Sun J Kang; Matthew D Hall; William H Theodore; Robert B Innis; Jan Mulder Journal: Epilepsia Date: 2018-07-21 Impact factor: 5.864
Authors: Andre Altmann; Mina Ryten; Martina Di Nunzio; Teresa Ravizza; Daniele Tolomeo; Regina H Reynolds; Alyma Somani; Marco Bacigaluppi; Valentina Iori; Edoardo Micotti; Rossella Di Sapia; Milica Cerovic; Eleonora Palma; Gabriele Ruffolo; Juan A Botía; Julie Absil; Saud Alhusaini; Marina K M Alvim; Pia Auvinen; Nuria Bargallo; Emanuele Bartolini; Benjamin Bender; Felipe P G Bergo; Tauana Bernardes; Andrea Bernasconi; Neda Bernasconi; Boris C Bernhardt; Karen Blackmon; Barbara Braga; Maria Eugenia Caligiuri; Anna Calvo; Chad Carlson; Sarah J A Carr; Gianpiero L Cavalleri; Fernando Cendes; Jian Chen; Shuai Chen; Andrea Cherubini; Luis Concha; Philippe David; Norman Delanty; Chantal Depondt; Orrin Devinsky; Colin P Doherty; Martin Domin; Niels K Focke; Sonya Foley; Wendy Franca; Antonio Gambardella; Renzo Guerrini; Khalid Hamandi; Derrek P Hibar; Dmitry Isaev; Graeme D Jackson; Neda Jahanshad; Reetta Kälviäinen; Simon S Keller; Peter Kochunov; Raviteja Kotikalapudi; Magdalena A Kowalczyk; Ruben Kuzniecky; Patrick Kwan; Angelo Labate; Soenke Langner; Matteo Lenge; Min Liu; Pascal Martin; Mario Mascalchi; Stefano Meletti; Marcia E Morita-Sherman; Terence J O'Brien; Jose C Pariente; Mark P Richardson; Raul Rodriguez-Cruces; Christian Rummel; Taavi Saavalainen; Mira K Semmelroch; Mariasavina Severino; Pasquale Striano; Thomas Thesen; Rhys H Thomas; Manuela Tondelli; Domenico Tortora; Anna Elisabetta Vaudano; Lucy Vivash; Felix von Podewils; Jan Wagner; Bernd Weber; Roland Wiest; Clarissa L Yasuda; Guohao Zhang; Junsong Zhang; Costin Leu; Andreja Avbersek; Maria Thom; Christopher D Whelan; Paul Thompson; Carrie R McDonald; Annamaria Vezzani; Sanjay M Sisodiya Journal: Neuropathol Appl Neurobiol Date: 2021-09-05 Impact factor: 8.090